Kodiak Sciences Inc.

KOD Healthcare Biotechnology

EPS
−1.94%
Free cash flow
−33.9%

Quarter to June 2026, against a year earlier

98.85 7.83 +8.60%
Market cap
$5.7B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
4.06 0.17 18.74 28.97 30.93 11.36 9.26 6.93 6.72 4.72
Net Debt/EBITDA
0.56 (0.34) 3.41 6.93 7.35 2.83 1.45 1.13 1.05 1.01
Debt/Equity
0.00 (0.14) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
31.13% 50.88% (458.06%) (21.92%) (22.07%) (35.04%) (60.72%) (74.22%) (84.70%) (149.49%)
ROA
(226.70%) (363.80%) (86.85%) (21.00%) (18.66%) (27.08%) (42.50%) (45.46%) (43.24%) (66.94%)
ROIC
0.00% 0.00% 0.00% (346.29%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(181.14%) 461.45% (47.79%) (14.42%) (14.07%) (37.53%) (68.14%) (70.77%) (70.88%) (90.35%)
Free Cash Flow per Share
(2.33) (2.38) (1.98) (1.05) (1.98) (4.74) (4.86) (3.73) (2.24) (2.57)
Book value per Share
(5.70) (9.15) 5.80 9.12 18.82 12.81 8.35 5.07 2.86 2.96
Free Cash Flow
(16.82) (17.86) (29.61) (39.58) (90.43) (245.57) (253.82) (195.61) (117.72) (136.51)
Other line items

Show all line items

Columns are period end dates